About us
B&A Oncomedical brings together a multidisciplinary team of researchers and pharmacology experts with a shared ambition: to develop innovative therapies for diseases where ionic homeostasis is disrupted, particularly cancers.
Our teams specialize in a broad range of technologies, from cell culture to advanced 3D tumoroid models, alongside cutting-edge electrophysiological expertise. This diverse set of ex vivo and in vitro approaches allows us to explore pathophysiological mechanisms in depth and precisely assess the full potential of tomorrow’s treatments.
Building on the strong scientific foundations established by Neurochlore, B&A Oncomedical is pursuing two major research avenues: first, tackling resistant brain tumors through the therapeutic combination of Mebendazole and Bumetanide, and second, developing next-generation NKCC1 inhibitors that offer greater efficacy while minimizing side effects.
Through this integrated approach, B&A Oncomedical aims to develop versatile treatment strategies based on restoring a balanced intracellular environment, with the primary goal of providing a concrete solution for treating resistant brain tumors.
Founders
Yehezkel Ben-Ari
Co-founder and president
Yehezkel Ben-Ari is a neurobiologist and neurophysiologist specializing in brain maturation processes. He developed the rodent model of temporal epilepsy, which enabled the decoding of its underlying mechanisms. Along with his team, he discovered the developmental sequences of synaptic neuronal activities, particularly those involving GABAergic transmission. His research has earned him prestigious awards, including the INSERM Grand Prize and recognitions from American and European epilepsy foundations.
Constance Hammond
Founder
Constance Hammond has combined her research career with university teaching and knowledge-sharing activities for various audiences. As an emeritus research director at Inserm and an expert in Parkinson’s disease, she is a recognized specialist in the functioning of basal ganglia neurons. She is the author of the textbook Cellular and Molecular Neurobiology (5th edition, Elsevier) and creator of MOOCs on Cellular Neurophysiology and Parkinson’s Disease (FUN). She also founded and presided over the association Tous Chercheurs.
Experts-researchers
Nathalia Lozovaya
Researcher, PhD
Présentation à venir
Anice Moumen
Researcher, PhD
Présentation à venir
Shan Min Chin
PhD Student
Présentation à venir
William Bourgeois
PhD Student
Présentation à venir
Experts-consultants
François Berger
Professor Researcher
Dr. François Berger is an expert in neuro-oncology and cell biology, specializing in translational research. Formerly the director of Clinatec, he sought to accelerate medical innovation by integrating clinical research into a technological environment. He then returned to the hospital to direct the INSERM U1205-BrainTech Lab unit, where he works on the development and clinical application of new technologies for brain diseases and cancer.
Eric Delpire
Professor Researcher
Eric Delpire, Ph.D., is a researcher and professor specializing in anesthesiology and molecular biophysics. He teaches at Vanderbilt University, where he directs the Division of Basic Sciences in Anesthesiology. His work focuses primarily on the regulation of ion transport in cells, particularly mechanisms involving ion cotransporters. His research is essential for better understanding certain neurological and renal diseases. He is recognized for his significant contributions to the field of molecular and cellular physiology.
Pascal George
Pharmaceutical Director
A former research director and senior executive in the pharmaceutical industry, Pascal George is currently president of the Society of Therapeutic Chemistry and an advisor to pharmaceutical research and development companies in Europe and Asia, as well as to national institutions. He is a former expert at the Ministry of Higher Education and Research, the National Agency for Research, and the Agency for the Evaluation of Higher Education and Research.
Denis Ravel
Pharmaceutical Director
Denis Ravel is the founder of Initial R&D Consulting, which supports startups in the development of innovative molecules. He has over 35 years of experience in pharmaceutical and biotechnology companies. He has supported over 50 projects in various therapeutic areas, such as cancer, metabolic, autoimmune, and neurodegenerative diseases, using chemical and biological molecules. This expertise allows him to address both preclinical and clinical aspects.
